Jasper Therapeutics(US:JSPR) Prnewswire·2025-09-25 20:46Core Viewpoint - A class action lawsuit has been filed against Jasper Therapeutics, Inc. for alleged violations of securities laws, specifically related to misleading statements regarding its manufacturing controls and clinical trials [1][2]. Group 1: Lawsuit Details - The class period for the lawsuit is from November 30, 2023, to July 3, 2025, with a deadline for lead plaintiff appointments set for November 18, 2025 [2]. - The complaint alleges that Jasper Therapeutics made false and misleading statements, particularly regarding its controls over third-party manufacturing and the risks posed to its clinical trials due to manufacturing partner issues [2]. Group 2: Shareholder Participation - Shareholders who purchased shares during the class period are encouraged to contact the DJS Law Group for potential lead plaintiff appointments, although this is not a requirement for recovery [2][3]. - Once registered, shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's progress, with no cost or obligation to participate [3]. Group 3: DJS Law Group's Role - DJS Law Group specializes in securities class actions and corporate governance litigation, focusing on enhancing investor returns through advocacy [4].